[Home ] [Archive]   [ فارسی ]  
Search in website

Advanced Search
..
:: Volume 6, Issue 6 (1-2012) ::
3 2012, 6(6): 0-0 Back to browse issues page
Platelet-Derived Growth Factor Promotes Periodontal Regeneration in Localized Osseous Defects: 36-Month Extension Results From a Randomized, Controlled, Double-Masked Clinical Trial
Myron Nevis * , Richard T.Kao , Michael K. McGuire , Pamela K. McClain , James E. Hinrichs , Bradley S. McAllister , Michael S. Reddy , Marc L. Nevins , Robert J. Genco , Samuel E. Lynch
Division of Periodontology, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA
Abstract:   (1617 Views)

 Background: Recombinant human platelet-derived growth factor (rhPDGF) is safe and effective for the treatment of periodontal defects in short-term studies up to 6 months in duration. We now provide results from a 36-month extension study of a multicenter, randomized, controlled clinical trial evaluating the effect and long-term stability of PDGF-BB treatment in patients with localized severe periodontal osseous defects.

  Methods: A total of 135 participants were enrolled from six clinical centers for an extension trial. Eighty-three individuals completed the study at 36 months and were included in the analysis. The study investigated the local application of β-tricalcium phosphate scaffold matrix with or without two different dose levels of PDGF (0.3 or 1.0 mg/mL PDGF-BB) in patients possessing one localized periodontal osseous defect. Composite analysis for clinical and radiographic evidence of treatment success was defined as percentage of cases with clinical attachment level (CAL) ≥2.7 mm and linear bone growth (LBG) ≥1.1 mm.

 Results: The participants exceeding this composite outcome benchmark in the 0.3 mg/mL rhPDGF-BB group went from 62.2% at 12 months, 75.9% at 24 months, to 87.0% at 36 months compared with 39.5%, 48.3%, and 53.8%, respectively, in the scaffold control group at these same time points (P <0.05). Although there were no significant increases in CAL and LBG at 36 months among all groups, there were continued increases in CAL gain, LBG, and percentage bone fill over time, suggesting overall stability of the regenerative response.

 Conclusion: PDGF-BB in a synthetic scaffold matrix promotes long-term stable clinical and radiographic improvements as measured by composite outcomes for CAL gain and LBG for patients possessing localized periodontal defects (ClinicalTrials.gov no. CT01530126).


 Source: Journal of Periodentology

 Full Text

Keywords: Bone regeneration, periodontics, platelet-derived growth factor, randomized controlled trial, regenerative medicine, tissue engineering
     
Type of Study: Research | Subject: Periodontology
Received: 2013/07/13 | Published: 2012/01/15
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nevis M, T.Kao R, K. McGuire M, K. McClain P, E. Hinrichs J, S. McAllister B, et al . Platelet-Derived Growth Factor Promotes Periodontal Regeneration in Localized Osseous Defects: 36-Month Extension Results From a Randomized, Controlled, Double-Masked Clinical Trial. 3 2012; 6 (6)
URL: http://idai.ir/article-1-1297-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 6, Issue 6 (1-2012) Back to browse issues page
جامعه اسلامی دندانپزشکان Islamic Dental Association of IRAN

کلیه حقوق سایت متعلق به جامعه اسلامی دندانپزشکان ایران است. تماس با ما

Persian site map - English site map - Created in 0.07 seconds with 34 queries by YEKTAWEB 4710